LD

Liz Dallimore

Argenica Therapeutics Limited | Chief Executive Officer, Managing Director
Dr Dallimore has over 20 years experience across Australia and the UK. Dr Dallimore has worked on data science, research engagement and commercialisation activities across a range of organisations and sectors. Prior to this, Dr Dallimore held roles in management consulting across Australia. Dr Dallimore has also contributed to industry and business organisations in board and advisory capacities. Dr Dallimore has worked at the Australian Neuromuscular Research Institute (now Perron Institute). Dr Dallimore is the member of the Risk Committee.

Company and Roles

Company
Title
Tenure
Since
AGN
Argenica Therapeutics Limited
  • Chief Executive Officer
  • Managing Director
4yrs, 6mthApr 2022

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
AGN
Argenica Therapeutics Limited
30/06/26N/A1,993,254N/AN/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
AGN
Argenica Therapeutics Limited
03/06/25
Issued
352,345$0.770$271,305Exercise of options
AGN
Argenica Therapeutics Limited
03/06/25
Cancelled
1,647,655$0.770$1,268,694Cancellation of securities
AGN
Argenica Therapeutics Limited
03/06/25
Exercise
352,345$0.770$271,305Exercise of options
AGN
Argenica Therapeutics Limited
08/08/24
Buy
1,590,909$0.790$1,256,818Exercise of options
AGN
Argenica Therapeutics Limited
08/08/24
Exercise
1,590,909$0.790$1,256,818Exercise of options